Anti-Yo Positive and Late-onset Paraneoplastic Cerebellar Degeneration Associated with Ovarian Carcinoma: A Case Report

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2017 Aug 11

PMID 28796031

Citations 6

Authors

Dan Cui

Li Xu

Wen-Yi Li

Wei-Dong Qian

Affiliations

Soon will be listed here.

Abstract

Rationale: Paraneoplastic cerebellar degeneration (PCD) is a rare nonmetastatic neurological complication often associated with ovarian, breast, and other gynecologic cancers. Anti-Yo is one of the antionconeural antibodies found in patients with PCD. It primarily emerges before a malignancy is detected.

Patient Concerns: In this report, we describe an unusual case involving a patient who exhibited anti-Yo-positive PCD 1 year after being diagnosed with ovarian cancer.

Diagnoses: Histopathology of the resected tissues and Antineuronal antibody testing.

Interventions: The patient was treated with intravenous immunoglobulin (IVIG, 1 g/d) for 1 week and a large-dose of methylprednisolone (0.4 g/kg/d) for 5 days. At the same time, underlying complications were prevented actively, and the peripheral nerves were protected.

Outcomes: Although most patients with anti-Yo-positive PCD do not improve after treatment, our patient significantly improved after receiving active and effective treatment.

Citing Articles

Anti-Yo paraneoplastic cerebellar degeneration in a patient with stage IV ovarian adenocarcinoma during bevacizumab maintenance therapy.

Giucca A, Morrison H, Wilson T, Cossburn M BMJ Case Rep. 2023; 16(5).

PMID: 37137547 PMC: 10163414. DOI: 10.1136/bcr-2022-251277.

An Etiological Investigation of Paraneoplastic Cerebellar Degeneration in Ovarian Cancer Patients: A Systematic Review.

Fidahussain A, Abid A, Paracha A, Jeevan V, Rueve J, Engelhardt M Cureus. 2022; 14(11):e31154.

PMID: 36483902 PMC: 9724195. DOI: 10.7759/cureus.31154.

Evaluation of the Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes in China.

Cai M, Qiao S, Lai Q, Zheng Y, Yang F, Fang G Front Immunol. 2022; 13:790400.

PMID: 35173717 PMC: 8841409. DOI: 10.3389/fimmu.2022.790400.

Potential effect of intravenous immunoglobulin against paraneoplastic cerebellar degeneration in progressive ovarian cancer.

Shibata T, Oishi T, Fukuoka Y, Nishikawa S, Iizuka N, Kato H Gynecol Oncol Rep. 2020; 34:100649.

PMID: 33005721 PMC: 7509787. DOI: 10.1016/j.gore.2020.100649.

Paraneoplastic cerebellar degeneration heralding recurrence of fallopian tube adenocarcinoma: A case report and literature review.

Cain A, Buckingham L, Staley A, Clark L Gynecol Oncol Rep. 2020; 33:100624.

PMID: 32904367 PMC: 7452669. DOI: 10.1016/j.gore.2020.100624.

References

Dropcho E . Paraneoplastic disorders: antineuronal antibodies and therapeutic options. Semin Neurol. 1994; 14(2):179-87. DOI: 10.1055/s-2008-1041076. View

Venkatraman A, Opal P . Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. Ann Clin Transl Neurol. 2016; 3(8):655-63. PMC: 4999597. DOI: 10.1002/acn3.328. View

Zaborowski M, Spaczynski M, Nowak-Markwitz E, Michalak S . Paraneoplastic neurological syndromes associated with ovarian tumors. J Cancer Res Clin Oncol. 2014; 141(1):99-108. PMC: 4282879. DOI: 10.1007/s00432-014-1745-9. View

Dalmau J, Gonzalez R, Lerwill M . Case records of the Massachusetts General Hospital. Case 4-2007. A 56-year-old woman with rapidly progressive vertigo and ataxia. N Engl J Med. 2007; 356(6):612-20. DOI: 10.1056/NEJMcpc069035. View

Negishi Y, Sakai K, Noguchi Y, Iwasaki N, Kawai N . Paraneoplastic cerebellar degeneration caused by ovarian clear-cell carcinoma. J Obstet Gynaecol Res. 2013; 40(2):614-7. DOI: 10.1111/jog.12212. View

Karim A, Jacob S . Immunological markers in neurological disorders. Ann Clin Biochem. 2011; 49(Pt 1):29-43. DOI: 10.1258/acb.2011.011140. View

Graus F, Dalmau J . Paraneoplastic neuropathies. Curr Opin Neurol. 2013; 26(5):489-95. DOI: 10.1097/WCO.0b013e328364c020. View

Bhat R, Steinman L . Innate and adaptive autoimmunity directed to the central nervous system. Neuron. 2009; 64(1):123-32. DOI: 10.1016/j.neuron.2009.09.015. View

Valpione S, Zoccarato M, Parrozzani R, Pigozzo J, Giometto B, Laveder F . Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma. J Neurol Sci. 2013; 335(1-2):210-2. DOI: 10.1016/j.jns.2013.08.026. View

10.

Bowyer S, Webb S, Millward M, Jasas K, Blacker D, Nowak A . Small cell lung cancer presenting with paraneoplastic limbic encephalitis. Asia Pac J Clin Oncol. 2011; 7(2):180-4. DOI: 10.1111/j.1743-7563.2010.01374.x. View

11.

Langer J, Lopes M, Fountain N, Pranzatelli M, Thiele E, Rust R . An unusual presentation of anti-Hu-associated paraneoplastic limbic encephalitis. Dev Med Child Neurol. 2012; 54(9):863-6. DOI: 10.1111/j.1469-8749.2012.04221.x. View

12.

Anderson N, Rosenblum M, Posner J . Paraneoplastic cerebellar degeneration: clinical-immunological correlations. Ann Neurol. 1988; 24(4):559-67. DOI: 10.1002/ana.410240413. View

13.

Hall D, Dyer M, PARKER Jr J . Ovarian cancer complicated by cerebellar degeneration: a paraneoplastic syndrome. Gynecol Oncol. 1985; 21(2):240-6. DOI: 10.1016/0090-8258(85)90259-8. View

14.

Peterson K, Rosenblum M, Kotanides H, Posner J . Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992; 42(10):1931-7. DOI: 10.1212/wnl.42.10.1931. View